RVNC - Revance Therapeutics misses by $0.15 misses on revenue February, 26 2019 04:09 PM Revance Therapeutics Inc. Revance Therapeutics (NASDAQ:RVNC): Q4 GAAP EPS of -$1.12 misses by $0.15. Revenue of $0.49M misses by $0.86M. Press Release More news on: Revance Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,